GILEAD SCIENCES News

DAX	8.472	0,2%	Dow	15.385	0,3%	Euro	1,2909	0,2%
ESt50	2.822	-0,1%	Nas	3.502	0,2%	Öl	103,8	-0,9%
TDax	968,9	-0,3%	Nikkei	15.381	0,1%	Gold	1.374	-1,5%

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News	Bilanz/GuV	Dividende/HV	Zertifikate	Depot
Times + Sales	Chart-Analyse	Analysen	Schätzungen	Termine	Optionsscheine	Watchlist
Börsenplätze	Chartvergleich	Kursziele	Vergleich	Profil	Knock-Outs	myHome
Orderbuch	Realtime Stuttgart	Fundamentalanalyse		Insidertrades	Fonds	Senden
Historisch	Realtime Push	myNews		im Forum	Anleihen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

myNews

Sprache:
Alle
DE
EN

Sortieren:
Datum
meistgelesen

14.05.13	Should You Buy Stock in Gilead After the Earnings Miss? (EN, MotleyFool)
08.05.13	Gilead Shows Some Heart (EN, MotleyFool)
04.05.13	Maximieren Sie Ihren Ertrag in nur 30 Minuten! (Freenet +370% / Technotrans +100% / Gilead +120% ...) (Der Aktionär)
02.05.13	Gilead Reports Interim Data From Phase 2 LONESTAR Study (EN, MotleyFool)
02.05.13	Stocks Up; Gilead and GM Rising (EN, Barrons)
02.05.13	Stocks Up; Gilead and GM Rising (EN, The Wall Street Journal Deutschland)
29.04.13	FDA Rejects 2 Gilead Sciences HIV Drugs (EN, MotleyFool)
23.04.13	Bristol Still Playing Catch-Up To Gilead In Hep C Drug Race (EN, TheStreet.com)
22.04.13	Futures Rising; Halliburton, Gilead Rising (EN, Barrons)
19.04.13	Worth Repeating: Vertex Is The Next Gilead Sciences (EN, TheStreet.com)
08.04.13	Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir for the Treatment of Hepatitis C (EN, MotleyFool)
03.04.13	Health Care's Elite Eight Stocks: Celgene vs. Gilead (EN, MotleyFool)
31.03.13	Health Care's Sweet 16 Stocks: Gilead vs. Amgen (EN, MotleyFool)
26.03.13	Gilead Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients (EN, MotleyFool)
25.03.13	Idenix Loses First Phase Of Patent Dispute With Gilead Sciences (EN, TheStreet.com)
23.03.13	Gilead Keeps on Building (EN, MotleyFool)
05.03.13	Gilead Announces Full 24-Week Phase 2 Results for Once-Daily Single Tablet HIV Regimen Containing Novel Prodrug Tenofovir Alafenamide (TAF) (EN, MotleyFool)
05.03.13	Movers & Shakers: Tuesday’s movers: Acura, Gilead, Apple (EN, MarketWatch)
01.03.13	Gilead Sciences to Present at the Cowen & Company 33rd Annual Health Care Conference on Monday, March 4 (EN, MotleyFool)
26.02.13	Is Gilead Sciences Destined for Greatness? (EN, MotleyFool)
21.02.13	Gilead, Teva Agree to End Patent Feud (EN, MotleyFool)
20.02.13	Gilead and Teva Reach Settlement Agreement in Viread® Patent Litigation (EN, MotleyFool)
09.02.13	Has Gilead Sciences Become the Perfect Stock? (EN, MotleyFool)
08.02.13	Gilead Sciences Completes Acquisition of YM BioSciences (EN, MotleyFool)
08.02.13	Gilead Sciences completes acquisition of YM BioSciences (EN, CNX)
07.02.13	This News Makes Gilead the Top Healthcare Pick (EN, MotleyFool)
05.02.13	YM BioSciences Announces Receipt of Final Court Order Approving the Plan of Arrangement with Gilead Sciences (EN, CNX)
05.02.13	Gilead Earnings Blaze a Star-Studded Future (EN, MotleyFool)
05.02.13	UPDATE: Gilead Posts Upbeat Q4 Results (EN, Benzinga earnings)
05.02.13	Gilead Sciences posts 15 percent rise in 4Q profit (EN, Yahoo)
04.02.13	Gilead Sciences Announces Fourth Quarter and Full Year 2012 Financial Results (EN, MotleyFool)
03.02.13	Stocks to Watch: Stocks to watch Monday: Gilead, Simon Property (EN, MarketWatch)
02.02.13	Gilead Sciences Earnings: An Early Look (EN, MotleyFool)
31.01.13	Foolish Preview: Gilead Earnings (EN, MotleyFool)
31.01.13	YM BioSciences Shareholders Approve Plan of Arrangement with Gilead Sciences (EN, CNX)
30.01.13	Forbes Earnings Preview: Gilead Sciences (EN, Forbes)
24.01.13	Gilead Initiates Phase 3 Clinical Program for Tenofovir Alafenamide, a Novel Low-Dose Prodrug for the Treatment of HIV (EN, MotleyFool)
18.01.13	YM BioSciences Inc. Plan of Arrangement with Gilead Sciences, Inc. Endorsed by Leading Independent Proxy Advisors ISS and Glass Lewis (EN, CNX)
08.01.13	Gilead, MacroGenics Ink Antibody Licensing Deal (EN, MotleyFool)
04.01.13	Gilead Sciences to Present at the 31st Annual JPMorgan Healthcare Conference on Monday, January 7 (EN, MotleyFool)

Seite: 12 3 4 5

21:34 Uhr	Updates zu Allianz, Deutsche Bank, Continental und E.ON
20:05 Uhr	Pfizer Stock Checkup for May
16:04 Uhr	ANALYSE-FLASH: Citigroup senkt Merck KGaA auf 'Least Preferred Stock' List
13:26 Uhr	From Novel Research to Innovative Medicines: GlaxoSmithKline Launches Discovery Fast Track Competition for Academic Researchers
11:55 Uhr	Biogen Idec Submits BLA to FDA for Approval of PLEGRIDY for Multiple Sclerosis
10:56 Uhr	Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis
10:30 Uhr	Biogen Idec reicht Zulassungsantrag für PLEGRIDY™ (Peginterferon Beta-1a) zur Behandlung der multiplen Sklerose bei der FDA ein
10:30 Uhr	Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis
00:20 Uhr	Dow Slips, Led Lower by Merck Stock
20.05.13	ROUNDUP/Aktien New York Schluss: Dow etwas leichter nach kurzem Höhenflug

Finanzen.net

Gilead Sciences Aktie [WKN: 885823 / ISIN: US3755581036]

Gilead Sciences News

Newssuche

Meistgelesene Gilead Sciences News 1M

Gilead Sciences Peer Group News